Skip to content

Study · Observational study · n = 2,471 · 2019

4 results

Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.

Mody R, Huang Q, Yu M, Zhao R, Patel H, Grabner M, Landó LF

Diabetes, obesity & metabolism9 Jan 2019Cited by 79 (Europe PMC)

PMID30520248 (opens in a new tab)PMCIDPMC6590811 (opens in a new tab)DOI10.1111/dom.13603 (opens in a new tab)PepBankPUB-30520248
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in US claims data, a significantly smaller proportion of patients initiating liraglutide were adherent than those initiating dulaglutide.

    In plain wordsIn US adults with type 2 diabetes, fewer people starting liraglutide stayed adherent than people starting dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseAdherence at 12 months compared with dulaglutide
    Study

    n = 2,471

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Adherence
    38.2%
    liraglutide
    Adherence
    51.2%
    dulaglutide

    Source sentences

    Summary
    Among those initiating dulaglutide there was a significantly higher proportion of adherent patients compared with the groups initiating liraglutide (51.2% vs. 38.2%; P < 0.001)
    1 context sentence
    Summary · context
    The present retrospective observational claims study included patients with type 2 diabetes (T2D) and ≥ 1 pharmacy claim for dulaglutide, liraglutide or exenatide once weekly from the HealthCore Integrated Research Database.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in US claims data, a significantly smaller proportion of patients initiating liraglutide were persistent at 12 months than those initiating dulaglutide.

    In plain wordsIn US adults with type 2 diabetes, fewer people starting liraglutide were still on treatment at 12 months than people starting dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreasePersistence at 12 months compared with dulaglutide
    Study

    n = 2,471

    Comparator
    Dulaglutide
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Persistence
    43.8%
    liraglutide
    Persistence
    55%
    dulaglutide

    Source sentences

    Summary
    At 12 months, 55% of patients in the dulaglutide group versus 43.8% in the liraglutide group (P < 0.001)
    1 context sentence
    Summary · context
    The present retrospective observational claims study included patients with type 2 diabetes (T2D) and ≥ 1 pharmacy claim for dulaglutide, liraglutide or exenatide once weekly from the HealthCore Integrated Research Database.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in US claims data, diabetes-related total costs did not differ significantly between liraglutide and dulaglutide.

    In plain wordsIn US adults with type 2 diabetes, yearly diabetes costs were not significantly different between liraglutide and dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeDiabetes-related total costs compared with dulaglutide
    Study

    n = 2,471

    Comparator
    Dulaglutide
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The diabetes-related total costs were not significantly different between the dulaglutide and the liraglutide group ($16,174 vs. $16,694; P = 0.184)
    1 context sentence
    Summary · context
    The present retrospective observational claims study included patients with type 2 diabetes (T2D) and ≥ 1 pharmacy claim for dulaglutide, liraglutide or exenatide once weekly from the HealthCore Integrated Research Database.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in US claims data, liraglutide gave a significantly smaller HbA1c reduction than dulaglutide.

    In plain wordsIn US adults with type 2 diabetes, HbA1c fell less with liraglutide than with dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction compared with dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −31.94 mmol/mol
    liraglutide
    HbA1c change
    −34.24 mmol/mol
    dulaglutide

    Source sentences

    Summary
    The dulaglutide group had a significantly greater reduction in HbA1c than the liraglutide group (-34.24 vs. -31.94 mmol/mol; P = 0.032)
    1 context sentence
    Summary · context
    The present retrospective observational claims study included patients with type 2 diabetes (T2D) and ≥ 1 pharmacy claim for dulaglutide, liraglutide or exenatide once weekly from the HealthCore Integrated Research Database.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.